Shingrix

Herpes zoster vaccine: Varicella zoster virus glycoprotein E antigen (recombinant, adjuvanted)

Prevention of herpes zoster & post-herpetic neuralgia in adults ≥50 yr; adults ≥18 yr at increased risk of herpes zoster.

IM Primary vaccination schedule of 2 doses (0.5 mL each): Initial dose followed by 2nd dose 2 mth later. If flexibility in the vaccination schedule is necessary, 2nd dose can be administered between 2 & 6 mth after the 1st dose. Immunodeficient or immunosuppressed individual 2nd dose can be given 1-2 mth after the initial dose.

Hypersensitivity.

Do not administer intravascularly or intradermally. SC administration is not recommended. Not indicated for prevention of primary varicella infection (chickenpox). Appropriate medical treatment & supervision should always be readily available in case of an anaphylactic event following vaccination. Postpone vaccination in subjects suffering from an acute severe febrile illness. Protective immune response may not be elicited in all vaccinees. No data to support replacing a dose of Shingrix w/ a dose of another herpes zoster vaccine. Administer w/ caution to individuals w/ thrombocytopenia or any coagulation disorder since bleeding may occur following IM administration. Limited data to support use in individuals w/ history of herpes zoster. May have minor influence on the ability to drive & use machines 2-3 days following vaccination. Preferable to avoid use during pregnancy. Effect on breast-fed infants of administration of Shingrix to their mothers has not been studied. Reports of increased risk of Guillain-Barré syndrome in a post-marketing observational study in individuals ≥65 yr during the 42 days following Shingrix vaccination.

Headache; GI symptoms (including nausea, vomiting, diarrhoea &/or abdominal pain); myalgia; inj site reactions (eg, pain, redness, swelling), fatigue, chills, fever. Inj site pruritus, malaise.

Can be given concomitantly w/ unadjuvanted inactivated seasonal flu vaccine, 23-valent pneumococcal polysaccharide vaccine (PPV23) or reduced antigen diphtheria-tetanus-acellular pertussis vaccine (dTpa); should be administered at different inj sites. More frequent adverse reactions of fever & shivering w/ PPV23 vaccine. Not recommended to concomitantly use w/ other vaccines.

Vaccines, Antisera & Immunologicals

J07BK - Varicella zoster vaccines ; Used for active immunizations.

P₁S₁S₃